| Identification | Back Directory | [Name]
Benzenesulfonamide, N-[5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluoro- | [CAS]
1621718-37-3 | [Synonyms]
PI3K/mTOR Inhibitor-13
Benzenesulfonamide, N-[5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluoro- | [Molecular Formula]
C20H13F2N5O3S | [MOL File]
1621718-37-3.mol | [Molecular Weight]
441.41 |
| Hazard Information | Back Directory | [Uses]
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF)[1][2]. | [in vivo]
Pharmacokinetic (PK) parameters of PI3K/mTOR Inhibitor-13[2]
| Species | Administration manner | Dose (mg/kg) | T1/2 (h) | AUClast (ng?h/mL) | Cl/F (L/h/kg) | Vss (L/kg) | F (%) | | Rat | Intravenous injection | 2 | 2.77 | 7069 | 0.29 | 0.85 | 94.75 | | Mice | Intravenous injection | 1 | 5.45 | 57059 | 0.02 | 0.13 | 79.3 | | Dog | Intravenous injection | 1 | 0.67 | 3672 | 0.27 | 0.23 | 108.5 | | Monkey | Intravenous injection | 1 | 9.70 | 5978 | 0.16 | 0.92 | 59.8 |
| [References]
[1] Cao S, et al. Pharmaceutical combination or pharmaceutical composition for treatment of fibrotic diseases. World Intellectual Property Organization. WO2020078445.
[2] Xi N, et al. Aromatic heterocyclic compounds, pharmaceutical composition containing compounds and application of pharmaceutical composition.China.CN103965199. |
|
|